PMID- 16886963
OWN - NLM
STAT- MEDLINE
DCOM- 20061121
LR  - 20220317
IS  - 0300-0664 (Print)
IS  - 0300-0664 (Linking)
VI  - 65
IP  - 2
DP  - 2006 Aug
TI  - Dendritic cells as potential adjuvant for immunotherapy in adrenocortical 
      carcinoma.
PG  - 215-22
AB  - OBJECTIVE: Adrenocortical carcinoma (ACC) is a rare malignancy associated with a 
      dismal prognosis. Dendritic cells (DCs) are professional antigen-presenting cells 
      leading to an antitumour immune response. The aim of this study was to elaborate 
      two methods of antigen delivery to DCs and to evaluate an immunotherapy protocol 
      in ACC patients. DESIGN/PATIENTS: Autologous DCs were pulsed with autologous 
      tumour lysate (TL). Fusion of DCs with tumour cells was based on a polyethylene 
      glycol method. Two patients with metastasized hypersecretory ACC were vaccinated 
      twice. MEASUREMENTS: In vitro data were quantified by measurement of PBMC 
      (peripheral blood mononuclear cell) responses and cytokine secretion and by flow 
      cytometry analyses. Clinical response was monitored by CT scan of tumour mass and 
      measurement of angiogenic factors. RESULTS: The maximum loading of TL was 
      obtained at 24 h as 48.2% (+/- 26.8%) of DCs were TL-positive. The DC/tumour cell 
      fusion efficacy was approximately 45% as shown by double positive staining for 
      ACTH receptor and DC-specific CD83. In vivo DC vaccination resulted in positive 
      delayed-type hypersensitivity skin reactions reflecting specific memory 
      T-lymphocyte reaction. In vitro analyses revealed specific T-cell proliferation 
      in patient 1 (stimulation index: 5.7 compared to pretreatment) and induction of 
      cytotoxic granzyme B secreting T cells in patient 2 (0.41% CD8 + cells vs. 0.06% 
      pretreatment) as indicators of specific cytotoxic T cells. Although angiogenic 
      serum markers could be stabilized, no impact on tumour growth could be observed. 
      CONCLUSION: Our data demonstrate that autologous dendritic cells induce 
      antigen-specific Th1 immunity in adrenocortical carcinoma. The clinical outcome, 
      however, was not improved in the patients studied here.
FAU - Papewalis, Claudia
AU  - Papewalis C
AD  - Department of Endocrinology, Diabetes and Rheumatology, University Hospital 
      Duesseldorf, Duesseldorf, Germany.
FAU - Fassnacht, Martin
AU  - Fassnacht M
FAU - Willenberg, Holger S
AU  - Willenberg HS
FAU - Domberg, Julia
AU  - Domberg J
FAU - Fenk, Roland
AU  - Fenk R
FAU - Rohr, Ulrich-Peter
AU  - Rohr UP
FAU - Schinner, Sven
AU  - Schinner S
FAU - Bornstein, Stefan R
AU  - Bornstein SR
FAU - Scherbaum, Werner A
AU  - Scherbaum WA
FAU - Schott, Matthias
AU  - Schott M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cancer Vaccines)
RN  - 78E4J5IB5J (Mitotane)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage
MH  - Adrenal Cortex Neoplasms/drug therapy/*therapy
MH  - Adrenocortical Carcinoma/drug therapy/secondary/*therapy
MH  - Adult
MH  - Antigens, Neoplasm/immunology
MH  - Antineoplastic Agents/therapeutic use
MH  - Cancer Vaccines/*administration & dosage
MH  - Dendritic Cells/*transplantation
MH  - Fatal Outcome
MH  - Flow Cytometry
MH  - Humans
MH  - Hybridomas
MH  - Hypersensitivity, Delayed/immunology
MH  - Injections
MH  - Male
MH  - Microscopy, Electron
MH  - Middle Aged
MH  - Mitotane/therapeutic use
MH  - Treatment Failure
EDAT- 2006/08/05 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/08/05 09:00
PHST- 2006/08/05 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/08/05 09:00 [entrez]
AID - CEN2576 [pii]
AID - 10.1111/j.1365-2265.2006.02576.x [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2006 Aug;65(2):215-22. doi: 
      10.1111/j.1365-2265.2006.02576.x.